{"id":140301,"date":"2022-06-09T04:02:47","date_gmt":"2022-06-09T09:02:47","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/06\/protein-discovery-reinvigorates-promising-new-therapeutic"},"modified":"2022-06-09T04:02:47","modified_gmt":"2022-06-09T09:02:47","slug":"protein-discovery-reinvigorates-promising-new-therapeutic","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/06\/protein-discovery-reinvigorates-promising-new-therapeutic","title":{"rendered":"Protein discovery reinvigorates promising new therapeutic"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/protein-discovery-reinvigorates-promising-new-therapeutic3.jpg\"><\/a><\/p>\n<p>Several years ago, a promising therapeutic using stem cell factor (SCF) emerged that could potentially treat a variety of ailments, such as ischemia, heart attack, stroke and radiation exposure. However, during clinical trials, numerous patients suffered severe allergic reactions and development of SCF-based therapeutics stopped.<\/p>\n<p>A research team led by engineers at The University of Texas at Austin has developed a related therapeutic that they say avoids these major allergic reactions while maintaining its therapeutic activity. The keys to the discovery, published recently in <i>Nature Communications<\/i>, were the use of a similar, membrane-bound version of SCF delivered in engineered lipid nanocarriers.<\/p>\n<p>\u201cWe envision this as something you can inject where you have lack of blood flow and it could induce <a href=\"https:\/\/medicalxpress.com\/tags\/blood+vessels\/\" rel=\"tag\" class=\"\">blood vessels<\/a> to grow in that area,\u201d said Aaron Baker, a professor in the Cockrell School of Engineering\u2019s Department of Biomedical Engineering, and one of the leaders on the project.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Several years ago, a promising therapeutic using stem cell factor (SCF) emerged that could potentially treat a variety of ailments, such as ischemia, heart attack, stroke and radiation exposure. However, during clinical trials, numerous patients suffered severe allergic reactions and development of SCF-based therapeutics stopped. A research team led by engineers at The University of [\u2026]<\/p>\n","protected":false},"author":556,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,38],"tags":[],"class_list":["post-140301","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-engineering"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/140301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=140301"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/140301\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=140301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=140301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=140301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}